Key result
Early post-ICI peak TnI threshold of 100 pg/mL perfectly identifies all clinically significant events.
Why the study?
Does a specific peak Troponin I threshold accurately identify clinically significant myocardial injury in patients initiating immune checkpoint inhibitors?
Observational (n=281)
No
Does a specific peak Troponin I threshold accurately identify clinically significant myocardial injury in patients initiating immune checkpoint inhibitors?
A peak troponin I threshold of 100 pg/mL within 3 months of immune checkpoint inhibitor initiation provides a highly specific and sensitive pragmatic trigger for evaluating ICI-associated myocarditis and other significant myocardial injuries.
Answers are grounded in this paper and cite their sources.
May support troponin I thresholds for ICI-myocarditis detection; hypothesis-generating and requires prospective validation before practice change.
Background: Troponin surveillance may facilitate early detection of immune checkpoint inhibitor (ICI)-associated myocarditis, but mild elevations and baseline abnormalities complicate interpretation. We assessed early post-ICI troponin I (TnI) dynamics and the performance characteristics of clinically applicable peak TnI thresholds within 3 months of ICI initiation.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2026) conducted an observational in Cancer patients receiving immune checkpoint inhibitors (n=281). Peak Troponin I >100 pg/mL vs. Peak Troponin I ≤100 pg/mL was evaluated on Clinically significant TnI elevation within 3 months of ICI initiation (100% sensitivity, 99.6% specificity, 83.3% PPV, 100% NPV). A peak troponin I threshold of 100 pg/mL within 3 months of immune checkpoint inhibitor initiation identified all clinically significant events with 100% sensitivity and 99.6% specificity.
Synapse has enriched 10 related papers. Consider them for comparative context: